期刊
NICOTINE & TOBACCO RESEARCH
卷 23, 期 3, 页码 495-504出版社
OXFORD UNIV PRESS
DOI: 10.1093/ntr/ntaa041
关键词
-
资金
- National Cancer Institute (NCI) [R01CA215155-01A1]
- NCI [R01 CA179422-01, P30 CA138292]
- US Fogarty International Center/NCI [1R01TW010664-01]
- NIH [SC3GM122628, R01 CA190347]
- USDHHS [3GM1226290FK0105-01-00]
- US FDA [R01CA204891, U01DA045537, R21DA046333]
- TRDRP [27IP-0041, 28IP-0022S]
The study found that most vape shops in the United States complied with FDA health warnings, free sampling bans, and minimum-age signage. However, there were concerns related to underage access, health claims, promotional strategies, and cannabidiol product offerings, indicating the need for further FDA and state regulatory efforts.
Introduction: Vape shops represent prominent, unique retailers, subject to Food and Drug Administration (FDA) regulation in the United States. Aims and Methods: This study assessed compliance of US vape shop retail marketing strategies with new regulations (eg, required age verification, prohibited free samples) and pre-implementation conditions for other regulations (eg, health warning labels on all nicotine products, required disclosures of e-liquid contents). Results: 95.0% of shops displayed minimum-age signage; however, mystery shoppers were asked for age verification at 35.6% upon entry and at 23.4% upon purchase. Although 85.5% of shops had some evidence of implementing FDA health warnings, 29.1% had signage indicating prohibited health claims, 16.3% offered free e-liquid samples, 27.4% had signage with cartoon imagery, and 33.3% were within two blocks of schools. All shops sold open-system devices, 64.8% sold closed-system devices, 68.2% sold their own brand of e-liquids, 42.5% sold e-liquids containing cannabidiol, 83.2% offered price promotions of some kind, and 89.9% had signage for product and price promotions. Conclusions: Results indicated that most shops complied with some implementation of FDA health warnings and with free sampling bans and minimum-age signage. Other findings indicatedconcerns related to underage access, health claims, promotional strategies, and cannabidiol product offerings, which call for further FDA and state regulatory/enforcement efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据